1563P - Increasing the earlier detection of lung cancer: A toolbox for change

Background

The global burden and mortality rate of lung cancer could be significantly reduced through increased early detection. Most people with lung cancer are currently diagnosed at an advanced stage, which is a major contributor to lung cancer being the leading cause of cancer-related death. Shifting the stage of lung cancer through earlier detection initiatives offers a unique opportunity to improve outcomes and survival rates. While targeted screening of people at high risk of lung cancer using low-dose computed tomography (LDCT) is the most effective means of detecting lung cancer at an early stage, large-scale LDCT screening programmes may not be currently feasible in many countries. Other early detection strategies are available that should collectively be assessed and adopted as appropriate in each country.

Methods

The Lung Cancer Policy Network, a global multi-stakeholder initiative of experts in lung cancer, has developed a report highlighting the opportunities for earlier detection strategies to improve outcomes for people with lung cancer. The report used a bespoke methodology to produce consensus-driven insights that explore earlier detection approaches in lung cancer. The report was informed by a review of existing peer-reviewed publications and grey literature, qualitative interviews and insights from Network members.

Results

The report explores the utility of various existing and emerging approaches and tools that can be used for the earlier detection of lung cancer. These include: public awareness campaigns; symptom-based detection and diagnosis; screening; incidental detection and technological innovation. Throughout the report, 12 case studies from different countries provide real-world examples of earlier detection tools. The report concludes with a series of policy recommendations to encourage national decision-makers to act to reduce mortality from lung cancer through the adoption of early detection approaches.

Conclusions

The report supports national decision-makers in making earlier detection an integral feature of cancer control plans. It explores the tools needed to take ambitious steps towards implementing feasible strategies that serve the differing needs of populations across the globe, and that will ultimately save lives.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The Health Policy Partnership.

Funding

The Lung Cancer Policy Network is a global multi-stakeholder initiative set up by the Lung Ambition Alliance. The Network is funded by AstraZeneca, Guardant Health, Johnson & Johnson, MSD and Siemens Healthineers. Secretariat is provided by The Health Policy Partnership, an independent health research and policy consultancy. All Network outputs are non-promotional, evidence based and shaped by the members, who provide their time for free. The Health Policy Partnership has been commissioned over the past 24 months to conduct non-promotional, non-product related policy projects for: Advanced Accelerator Applications, AEPHCPO (Novartis UAE), Alexion, All.Can International, Amazon Web Services, Amgen, Arythmia Alliance, AstraZeneca, Batten Disease Family Association, Bayer, Bristol Myers Squibb (BMS), Boehringer Ingelheim European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Society of Anaesthesiology and Intensive Care (ESAIC), GSK, Global Heart Hub (GHH), Guardant Health, Indivior, Initiative Herzklappe e.V, International Cardiomyopathy Network Janssen Pharmaceutica NV, Johnson & Johnson, Life Technologies Europe BV, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Sophia Genetics, Stemline Therapeutics, Stockholm Institute for Research (SIR) UCB Biopharma, Vifor Pharma, and Vision Zero Cancer.

Disclosure

H. Wilcox: Financial Interests, Personal, Full or part-time Employment, The Health Policy Partnership (the organization where Helena Wilcox is employed) provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson, Merck, Sharpe & Dohme (MSD) and Siemens Healthineers for the research that and development of the implementation framework which is described in this abstract. Helena Wilcox has not received any direct consultancy fees for any of this work.: The Health Policy Partnership; Financial Interests, Institutional, Full or part-time Employment, The Health Policy Partnership has been commissioned over the past 24 months to conduct non-promotional, non-product related policy projects for: Advanced Accelerator Applications, AEPHCPO (Novartis UAE), Alexion, All.Can International, Amazon Web Services, Amgen, Arythmia Alliance, AstraZeneca, Batten Disease Family Association, Bayer, Bristol Myers Squibb (BMS), Boehringer Ingelheim European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Society of Anaesthesiology and Intensive Care (ESAIC), GSK, Global Heart Hub (GHH), Guardant Health, Indivior, Initiative Herzklappe e.V, International Cardiomyopathy Network Janssen Pharmaceutica NV, Johnson & Johnson, Life Technologies Europe BV, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Sophia Genetics, Stemline Therapeutics, Stockholm Institute: The Health Policy Partnership; Non-Financial Interests, Member: The International Association for the Study of Lung Cancer. E. Wheeler: Financial Interests, Personal, Writing Engagement, The Health Policy Partnership (the organization where Eleanor Wheeler is employed) provides Secretariat duties for the Lung Cancer Policy Network, which received funding from AstraZeneca, Guardant, Medtronic, Johnson & Johnson, Merck, Sharpe & Dohme (MSD) and Siemens Healthineers for the research that and development of the implementation framework which is described in this abstract. Eleanor Wheeler has not received any direct consultancy fees for any of this work.: The Health Policy Partnership; Financial Interests, Institutional, Full or part-time Employment, The Health Policy Partnership has been commissioned over the past 24 months to conduct non-promotional, non-product related policy projects for: Advanced Accelerator Applications, AEPHCPO (Novartis UAE), Alexion, All.Can International, Amazon Web Services, Amgen, Arythmia Alliance, AstraZeneca, Batten Disease Family Association, Bayer, Bristol Myers Squibb (BMS), Boehringer Ingelheim European Federation of Pharmaceutical Industries and Associations (EFPIA), Elekta, European Society of Anaesthesiology and Intensive Care (ESAIC), GSK, Global Heart Hub (GHH), Guardant Health, Indivior, Initiative Herzklappe e.V, International Cardiomyopathy Network Janssen Pharmaceutica NV, Johnson & Johnson, Life Technologies Europe BV, Medicines for Europe, Medtronic, Merck Sharpe & Dohme (MSD), Neuroendocrine Cancer UK, National Institute for Prevention and Cardiovascular Health (NIPC), Novartis, Novo Nordisk, Philips, Roche Diagnostics, Sanofi, Sophia Genetics, Stemline Therapeutics, Stockholm Institute: The Health Policy Partnership; Non-Financial Interests, Member: The International Association for the Study of Lung Cancer (IASLC).